Cargando…

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)

BACKGROUND AND AIMS: Nonalcoholic steatohepatitis (NASH) is considered as a pivotal stage in nonalcoholic fatty liver disease (NAFLD) progression, given that it paves the way for severe liver injuries such as fibrosis and cirrhosis. The etiology of human NASH is multifactorial, and identifying relia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vandel, Jimmy, Dubois‐Chevalier, Julie, Gheeraert, Céline, Derudas, Bruno, Raverdy, Violetta, Thuillier, Dorothée, Gaal, Luc, Francque, Sven, Pattou, François, Staels, Bart, Eeckhoute, Jérôme, Lefebvre, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048532/ https://www.ncbi.nlm.nih.gov/pubmed/32394476 http://dx.doi.org/10.1002/hep.31312

Ejemplares similares

GIANT: galaxy-based tool for interactive analysis of transcriptomic data
por: Vandel, Jimmy, et al.
Publicado: (2020)

NASH-related increases in plasma bile acid levels depend on insulin resistance
por: Grzych, Guillaume, et al.
Publicado: (2020)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients
por: Margerie, Daniel, et al.
Publicado: (2019)

Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis: Molecular and Multicellular Control of Evolving Diseased States
por: Eeckhoute, Jérôme
Publicado: (2022)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

A dynamic CTCF chromatin binding landscape promotes DNA hydroxymethylation and transcriptional induction of adipocyte differentiation
por: Dubois-Chevalier, Julie, et al.
Publicado: (2014)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

The RBM14/CoAA-interacting, long intergenic non-coding RNA Paral1 regulates adipogenesis and coactivates the nuclear receptor PPARγ
por: Firmin, François F., et al.
Publicado: (2017)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Plasma levels of vitamin E and carotenoids are decreased in patients with nonalcoholic steatohepatitis (NASH)
por: Erhardt, A, et al.
Publicado: (2011)

A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Hadefi, Alia, et al.
Publicado: (2021)

The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH)
por: Salvoza, Noel, et al.
Publicado: (2022)

The logic of transcriptional regulator recruitment architecture at cis-regulatory modules controlling liver functions
por: Dubois-Chevalier, Julie, et al.
Publicado: (2017)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

An extended transcription factor regulatory network controls hepatocyte identity
por: Dubois‐Chevalier, Julie, et al.
Publicado: (2023)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Omega-3 Polyunsaturated Fatty Acids Prevent Nonalcoholic Steatohepatitis (NASH) and Stimulate Adipogenesis
por: Antraco, Vitor Jacó, et al.
Publicado: (2021)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs
por: Galatou, Eleftheria, et al.
Publicado: (2022)

Validation of NASH-CHECK: a novel patient-reported outcome measure for nonalcoholic steatohepatitis
por: Twiss, James, et al.
Publicado: (2023)

Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver
por: Igreja Sá, Ivone Cristina, et al.
Publicado: (2020)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH)
por: Sookoian, Silvia, et al.
Publicado: (2016)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Lipidomic and transcriptomic analysis of western diet-induced nonalcoholic steatohepatitis (NASH) in female Ldlr (-/-) mice
por: Garcia-Jaramillo, Manuel, et al.
Publicado: (2019)

acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study
por: Wu, Xi-Xi, et al.
Publicado: (2021)

Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial
por: Sato, Masaya, et al.
Publicado: (2023)

Therapeutic approaches for non-alcoholic steatohepatitis
por: Van Gaal, Luc F., et al.
Publicado: (2021)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f9bku2j10368rjpn9587parh3f